Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MGC026 Dose Escalation · 1 trial · 22 indications
| Arm | Type | Description |
|---|---|---|
| Cohort 1 | EXPERIMENTAL | MGC026 is a topoisomerase 1 inhibitor (TOP1i)-based ADC that targets B7-H3 administered IV every 3 weeks. |
| Cohort 2 | EXPERIMENTAL | - |
| Cohort 3 | EXPERIMENTAL | - |
| Cohort 4 | EXPERIMENTAL | - |
| Cohort 5 | EXPERIMENTAL | - |
| Cohort 6 | EXPERIMENTAL | - |
| Expansion cohort 1 | EXPERIMENTAL | - |
| Expansion cohort 2 | EXPERIMENTAL | - |
| Expansion cohort 3 | EXPERIMENTAL | - |
| Expansion cohort 4 | EXPERIMENTAL | - |
| Expansion Cohort 5 | EXPERIMENTAL | - |
| Expansion Cohort 6 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MGC026 Dose Escalation | BIOLOGICAL | Escalating doses of MGC026 |
| MGC026 Dose for Expansion | BIOLOGICAL | MGC026 recommended dose for expansion |
Inclusion Criteria: * Adults ≥ 18 years old, able to provide informed consent * Adequate performance and laboratory parameters * Availability of archival or formalin-fixed paraffin-embedded tumor tissue sample. Participants may undergo a fresh tumor biopsy to obtain a specimen for testing if an arc...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
MGC026 is an investigational monoclonal antibody being studied for the treatment of advanced solid tumors, including metastatic cancer and various specific cancers such as non-small cell lung cancer, bladder cancer, melanoma, and breast cancer. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
MGC026 is being developed by MacroGenics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol MGNX. The company is conducting a Phase 1 clinical trial to evaluate the safety and efficacy of MGC026 in patients with advanced solid tumors.
MGC026 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The ongoing Phase 1 trial is currently recruiting participants to assess the drug's safety, tolerability, and preliminary efficacy in advanced solid tumors.
MGC026 is being evaluated in a single Phase 1 clinical trial with the identifier NCT06242470, titled "A Study of MGC026 in Participants With Advanced Solid Tumors." This trial is actively recruiting up to 250 participants across the United States, Australia, and the United Kingdom.
The MGC026 Phase 1 trial covers a wide range of advanced solid tumors, including squamous cell carcinoma of the head and neck, non-small cell lung cancer, small-cell lung cancer, bladder cancer, sarcoma, endometrial cancer, melanoma, castration-resistant prostate cancer, cervical cancer, colorectal cancer, gastric cancer, gastro-esophageal cancer, pancreatic cancer, clear cell renal cell carcinoma, hepatocellular carcinoma, platinum-resistant ovarian cancer, breast cancer, ovarian cancer, and esophageal squamous cell cancer.